Invitrogen to Screen Third Party Cell-Culture Technologies; Clarifies Viropro Deal | GenomeWeb
NEW YORK (GenomeWeb News) — Invitrogen has started a new program to screen technologies from third party companies against its own cell-culture products, the company said today.
Invitrogen also clarified the terms of its recent collaboration with Viropro, which falls under this screening program, saying it would not pay royalties or take commercial interest in any licensing of the technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.